{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:52:13Z","timestamp":1778637133559,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,2,29]],"date-time":"2012-02-29T00:00:00Z","timestamp":1330473600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s11523-012-0214-0","type":"journal-article","created":{"date-parts":[[2012,2,28]],"date-time":"2012-02-28T08:42:10Z","timestamp":1330418530000},"page":"145-149","source":"Crossref","is-referenced-by-count":37,"title":["Pazopanib therapy for cerebellar hemangioblastomas in von Hippel\u2013Lindau disease"],"prefix":"10.1007","volume":"7","author":[{"given":"Betty Y. S.","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Jonasch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian E.","family":"McCutcheon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,2,29]]},"reference":[{"key":"214_CR1","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/jama.300.11.1334","volume":"300","author":"JA Butman","year":"2008","unstructured":"Butman JA, Linehan WM, Lonser RR (2008) Neurologic manifestations of von Hippel\u2013Lindau disease. JAMA 300:1334\u20131342","journal-title":"JAMA"},{"key":"214_CR2","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(03)13643-4","volume":"361","author":"RR Lonser","year":"2003","unstructured":"Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH (2003) von Hippel\u2013Lindau disease. Lancet 361:2059\u20132067","journal-title":"Lancet"},{"issue":"1 Suppl","key":"214_CR3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3171\/jns.2003.98.1.0082","volume":"98","author":"JE Wanebo","year":"2003","unstructured":"Wanebo JE, Lonser RR, Glenn GM, Oldfield EH (2003) The natural history of hemangioblastomas of the central nervous system in patients with von Hippel\u2013Lindau disease. J Neurosurg 98(1 Suppl):82\u201394","journal-title":"J Neurosurg"},{"key":"214_CR4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0300-2977(01)00165-6","volume":"59","author":"FJ Hes","year":"2001","unstructured":"Hes FJ, van der Luijt RB, Lips CM (2001) Clinical management of von Hippel\u2013Lindau (VHL) disease. Neth J Med 59:225\u2013234","journal-title":"Neth J Med"},{"key":"214_CR5","first-page":"324","volume":"53","author":"JM Ammerman","year":"2006","unstructured":"Ammerman JM, Lonser RR, Dambrosia J, Butman J, Oldfield EH (2006) Long-term natural history of hemangioblastomas in von Hippel\u2013Lindau disease: implications for treatment. Clin Neurosurg 53:324\u2013331","journal-title":"Clin Neurosurg"},{"key":"214_CR6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11060-010-0244-3","volume":"101","author":"LR Rogers","year":"2011","unstructured":"Rogers LR, LoRusso P, Nadler P, Malik G, Shields A, Kaelin W (2011) Erlotinib therapy for central nervous system hemangioblastomatosis associated with von Hippel\u2013Lindau disease: a case report. J Neuro Oncol 101:307\u2013301","journal-title":"J Neuro Oncol"},{"key":"214_CR7","first-page":"510","volume":"7","author":"M Niemela","year":"2001","unstructured":"Niemela M, Maenpaa H, Salven P, Summanen P, Poussa K, Laatikainen L, Jaaskelainen J, Joensuu H (2001) Interferon-2a therapy in 18 hemangioblastomas. Clin Cancer Res 7:510\u2013516","journal-title":"Clin Cancer Res"},{"key":"214_CR8","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.291.8.943","volume":"291","author":"S Madhusudan","year":"2004","unstructured":"Madhusudan S, Deplanque G, Braybrooke JP, Cattell E, Harris AL (2004) Antiangiogenic therapy for von Hippel\u2013Lindau disease. JAMA 291:943\u2013944","journal-title":"JAMA"},{"key":"214_CR9","doi-asserted-by":"crossref","unstructured":"Jonasch E, McCutcheon IE, Waguespack SG, Wen S, Do KA, Davis DW, Zhang Y, Smith L, Tamboli P, Tannir NM, Gombos DS, Fuller GN and Matin SF (2011) Pilot trial of sunitinib therapy in patients with von Hippel\u2013Lindau disease. Ann Oncol, accepted","DOI":"10.1093\/annonc\/mdr011"},{"key":"214_CR10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/sj.bjc.6606084","volume":"104","author":"ME Gore","year":"2011","unstructured":"Gore ME, Larkin JMG (2011) Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Br J Cancer 104:399\u2013406","journal-title":"Br J Cancer"},{"key":"214_CR11","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10144","volume":"473","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298\u2013307","journal-title":"Nature"},{"key":"214_CR12","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/11205480-000000000-00000","volume":"24","author":"M Sanford","year":"2010","unstructured":"Sanford M, Keating GM (2010) Pazopanib. BioDrugs 24:279\u2013286","journal-title":"BioDrugs"},{"key":"214_CR13","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"28","author":"HS Friedman","year":"2009","unstructured":"Friedman HS, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas Mk, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 28:4733\u20134740","journal-title":"J Clin Oncol"},{"key":"214_CR14","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.2009.26.3988","volume":"28","author":"T Batchelor","year":"2010","unstructured":"Batchelor T, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK (2010) Phase II study of cediranib, an oral pan-endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28:2817\u20132823","journal-title":"J Clin Oncol"},{"key":"214_CR15","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/neuonc\/noq025","volume":"12","author":"FM Iwamoto","year":"2010","unstructured":"Iwamoto FM, Lamborn KR, Robins I, Mehta MP, Chang SM, Butowski NA, DeAngelis LM, Abrey LE, Zhang WT, Prados MD, Fine HA (2010) Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North America Brain Tumor Consortium Study 06-02). Neuro-Oncology 12:855\u2013861","journal-title":"Neuro-Oncology"},{"key":"214_CR16","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1586\/era.10.38","volume":"10","author":"RM Bukowski","year":"2010","unstructured":"Bukowski RM (2010) Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma. Expert Rev Anticancer Ther 10:635\u2013645","journal-title":"Expert Rev Anticancer Ther"},{"key":"214_CR17","first-page":"327","volume":"9","author":"DM Mendel","year":"2003","unstructured":"Mendel DM, Laird D, Xin X, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic pharmacodynamic relationship. Clin Cancer Res 9:327\u2013337","journal-title":"Clin Cancer Res"},{"key":"214_CR18","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.cco.0000142076.52721.b3","volume":"16","author":"EC Kaal","year":"2004","unstructured":"Kaal EC, Vecht CJ (2004) The management of brain edema in brain tumors. Curr Opin Oncol 16:593\u2013600","journal-title":"Curr Opin Oncol"},{"key":"214_CR19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58\u201362","journal-title":"Science"},{"key":"214_CR20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/neuonc\/nop027","volume":"12","author":"JF Groot De","year":"2010","unstructured":"De Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji YJ, Conrad CA (2010) Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro-Oncology 12:233\u2013242","journal-title":"Neuro-Oncology"},{"key":"214_CR21","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/sj.bjc.6605366","volume":"101","author":"R Kumar","year":"2009","unstructured":"Kumar R, Crouthamel MC, Rominger DH, Gontarek RR, Tummino PJ, Levin RA, King AG (2009) Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 101:1717\u20131723","journal-title":"Br J Cancer"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-012-0214-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-012-0214-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-012-0214-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T16:15:10Z","timestamp":1559405710000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-012-0214-0"}},"subtitle":["Case report"],"short-title":[],"issued":{"date-parts":[[2012,2,29]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["214"],"URL":"https:\/\/doi.org\/10.1007\/s11523-012-0214-0","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,29]]}}}